1. Home
  2. FRPH vs REPL Comparison

FRPH vs REPL Comparison

Compare FRPH & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FRP Holdings Inc.

FRPH

FRP Holdings Inc.

N/A

Current Price

$22.14

Market Cap

420.6M

Sector

Finance

ML Signal

N/A

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

N/A

Current Price

$15.96

Market Cap

454.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FRPH
REPL
Founded
1986
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
420.6M
454.6M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
FRPH
REPL
Price
$22.14
$15.96
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$5.67
AVG Volume (30 Days)
95.7K
7.1M
Earning Date
04-10-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$42,846,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.57
N/A
52 Week Low
$20.53
$1.50
52 Week High
$26.32
$15.89

Technical Indicators

Market Signals
Indicator
FRPH
REPL
Relative Strength Index (RSI) 51.09 61.99
Support Level $21.92 $9.01
Resistance Level $24.57 $15.71
Average True Range (ATR) 0.54 1.12
MACD 0.15 0.06
Stochastic Oscillator 66.09 90.16

Price Performance

Historical Comparison
FRPH
REPL

About FRPH FRP Holdings Inc.

FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, industrial, and office (the Development Segment), and (iv) management of mixed-use residential/retail properties owned through joint ventures.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: